Washington | 91-1549568 | |
(State or other jurisdiction of | (IRS Employer | |
incorporation) | Identification No.) |
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Amendment No. 4 makes the following material amendments to the Agreement:
- An additional extension of the exclusivity period for the sublicense granted to Targeted Genetics under the Agreement; and
- A grant to the licensor of the license underlying the Agreement, Children's Hospital Research Foundation and Children's Hospital Inc. ("Licensor"), of the right to use the patent rights, products and processes sublicensed to Targeted Genetics under the Agreeme nt for research and/or educational purposes and, subject to specified limitations, to manufacture AAV vectors for use by Licensor and certain non-commercial entities for educational and/or research activities, including clinical trials up to Phase II.
Targeted Genetics Corporation | ||||||||
Date: May 29, 2009 | By: | /s/ David J. Poston | ||||||
David J. Poston | ||||||||
Vice President Finance and Chief Financial Officer | ||||||||